Stock Details

Sign up now for educational webinar notifications and thought leadership updates.

Join us for In the Money with options strategist and CNBC contributor Dan Nathan for a weekly take on the market. Watch now.

EMMAUS LIFE SCIENCES INC

1.55Up 0.15 (10.714286 %)as of 11:01:05am ET 08/31/2021

Bid 1.42
Bid Size 1500
Ask 1.52
Ask Size 201
Open 1.41
Day High 1.55
Day Low 1.40
Previous Close 1.40
52-Week High 1.89
02/04/2021
52-Week Low 0.7001
11/10/2020
Price Performance (Last 52 Weeks)-7.89%
Held by ETPsNo
Volume 10,054
90-Day Average Volume 7,680
Primary Exchange OTC Markets
Index Not In
S&P 500®
DJIA®
NASDAQ 100®
Options No

Detailed Quote

TODAY 2D 5D 10D 1M 3M 6M YTD 1Y 3Y 5Y 10Y

DELAYED DATA AS OF

Show/Hide



No

EMMA currently has no events.

Events

More News & Events

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder…

View more

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

View less

Sector (GICS®)

Health Care

Industry (GICS®)

Pharmaceuticals

Environmental, Social & Governance Summary (ESG)

 

Secure.

ESG ratings enable you to leverage independent ESG research to evaluate how companies are managing ESG risks and addressing ESG opportunities. Learn more

To access the latest ESG Research, Visit the new Stock Dashboard

Full Time Employees: 58

Executives  Secure.

www.emmausmedical.com

21250 Hawthorne Boulevard, Suite 800
Torrance, CA 90503
United States of America

1-310 214 0065

  • Equity Summary Score -active tab
  • All Opinions

The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....

Log in to view the Equity Summary Score for EMMA

  • Equity Summary Score
  • All Opinions -active tab

Log in to view all Analyst Opinions for EMMA

Company Research Highlights® Report (PDF) Requires

VARIOUS THIRD PARTIES

This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.

Compustat ® Company Report Requires

S&P Global

This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts.

*Generated reports are built dynamically when you select them. Reports may not be available for some symbols. Select the link to check availability for this symbol.

EMMA Industry Comparison:

EMMAIndustry AveragePercentile
in Industry
Market Capitalization$69.04M$41.10B29th
Total Return (1 Year Annualized)
AS OF 04/28/2021 
-7.89%+22.51%44th
Beta--0.5949th
EPS (TTM)
AS OF 12/31/2020 title=
--$2.9182nd
Current Consensus EPS Estimate------
EPS Growth
(TTM vs. Prior TTM)
---132.14%--
P/E (TTM)
AS OF 08/30/2021
NM56.46--
Dividend Yield (Annualized)------
Total Revenue (TTM)
AS OF 12/31/2020
$23.17M$47.42B76th
Revenue Growth
(TTM vs Prior TTM)
--+23.73%--
Shares Outstanding49,312,0002,740,613,12045th
Institutional Ownership0.00%46.11%5th
† The Equity Summary Score provided by Thomson Reuters StarMine is current as of the date specified. There may be differences between the Equity Summary Score analyst count and the number of underlying analysts listed. Due to the timing in receiving ratings changes into the Equity Summary Score model, the Equity Summary Score analyst count may lag the ratings count displayed by one or more days. There may also be analyst count variations for symbols with multiple share classes and ADRs. More details on Equity Summary Score calculation are included in the Understanding and Using the Equity Summary Score Methodology (PDF).

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partners share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

455221.19

Say hello

Find us at the office

Chappa- Adamitis street no. 38, 81811 Tripoli, Libya

Give us a ring

Alda Runion
+69 213 130 910
Mon - Fri, 10:00-22:00

Say hello